RT Journal Article
SR Electronic
T1 Rapid response to a measles outbreak in Ifanadiana District, Madagascar
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.30.20143768
DO 10.1101/2020.11.30.20143768
A1 Finnegan, Karen E.
A1 Haruna, Justin
A1 Cordier, Laura F.
A1 Razafinjato, Benedicte
A1 Rakotonirina, Luc
A1 Randrianambinina, Andriamihaja
A1 Rakotozafy, Emmanuel
A1 Andriamihaja, Benjamin
A1 Garchitorena, Andres
A1 Bonds, Matthew H.
A1 Ouenzar, Mohammed Ali
YR 2020
UL http://medrxiv.org/content/early/2020/12/02/2020.11.30.20143768.abstract
AB In 2019, Madagascar experienced the nation’s largest documented measles outbreak ever. From September 2018 to January 2020, nearly 225,000 individuals were infected, slightly more than 1,000 of whom died. Madagascar is one of the poorest countries in the world with one of the least funded health systems. Here, we present the experience of how Madagascar’s Ministry of Health (MoH) partnered with a non-governmental organization, PIVOT, to rapidly respond to a measles outbreak in the rural district of Ifanadiana, in the southeast of the country. The epidemic reached Ifanadiana in January of 2019. By August, there were more than 4,800 identified cases of suspected measles, including 157 hospitalizations. Over the course of two weeks in February 2019, the MoH and PIVOT mobilized nine teams of 220 total staff to vaccinate 69,949 children aged 6 months to 10 years at schools and community events. Surrounding the campaign, health workers were trained in measles identification and provided with medication for symptom management. The measles response required overcoming health system weaknesses and geographic barriers which are endemic throughout the country and create chronic challenges for the provision of routine preventive and curative care. This response demonstrates that rapid mobilization of an organized health system response is feasible even in hard-to-reach areas.KEY POINTSMadagascar experienced the island’s worst measles outbreak in history as a result of low vaccination coverage.In Ifanadiana District, the Ministry of Health and a non-governmental health organization collaborated to respond to the measles outbreak with a mass vaccination campaign, sensitization, and provision of supplies to health facilities for the management of disease complications.The measles outbreak in Madagascar highlights the need for an increased focus on routine preventive care, especially in hard-to-reach communities; calls attention to the consequences of ruptures in the care continuum; and highlights the need for timely, continuous, de-centralized epidemiologic data.The response to the outbreak in one rural district is evidence that health care can be delivered in remote areas.Competing Interest StatementKEF, JH, LFC, BR, LR, BA, AG, MHB, and MAO received salary support from PIVOT. AR and ER received salary support from Madagascar's Ministry of Public Health.Funding StatementNo external funding was received for the preparation of this manuscript. Program activities which are reported on were funded by grants and donations received by PIVOT.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This work uses publicly available data and was authorized by the leadership of Madagascar's Ministry of Public Health. This study was determined to be non human subjects research by the IRB at Harvard University.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe corresponding author can provide information on the process of accessing the data.